These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27490760)

  • 1. Prognostic Significance of High Ki-67 Index and Histogenetic Subclassification in Primary Central Nervous System Lymphoma.
    Cho U; Oh WJ; Hong YK; Lee YS
    Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):254-262. PubMed ID: 27490760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification.
    Bhattacharyya I; Chehal HK; Cohen DM; Al-Quran SZ
    Head Neck Pathol; 2010 Sep; 4(3):181-91. PubMed ID: 20533006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.
    Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ
    Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases.
    Hattab EM; Martin SE; Al-Khatib SM; Kupsky WJ; Vance GH; Stohler RA; Czader M; Al-Abbadi MA
    Mod Pathol; 2010 Feb; 23(2):235-43. PubMed ID: 19935644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.
    Koh YW; Hwang HS; Park CS; Yoon DH; Suh C; Huh J
    Leuk Lymphoma; 2015; 56(9):2630-6. PubMed ID: 25573205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An immunohistochemical study of diffuse large B-cell lymphoma with molecular subtyping based on Hans algorithm.
    Ananthamurthy A; Murali M
    Indian J Pathol Microbiol; 2024 Jul; 67(3):564-568. PubMed ID: 38394429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GCB-type is a favorable prognostic factor in primary CNS diffuse large B-cell lymphomas.
    Marcus C; Maragkos GA; Alterman RL; Uhlmann E; Pihan G; Varma H
    J Clin Neurosci; 2021 Jan; 83():49-55. PubMed ID: 33339691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Subgrouping and outcome prediction of diffuse large B-cell lymphoma by immunohistochemistry].
    Ye ZY; Cao YB; Lin TY; Lin HL
    Zhonghua Bing Li Xue Za Zhi; 2007 Oct; 36(10):654-9. PubMed ID: 18194597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.
    van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM
    J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
    Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
    Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and Clinical Significance of Ki-67, CD10, BCL6, MUM1, c-MYC, and EBV in Diffuse Large B Cell Lymphoma Patients.
    Sadeghipour A; Taha SR; Shariat Zadeh M; Kosari F; Babaheidarian P; Fattahi F; Abdi N; Tajik F
    Appl Immunohistochem Mol Morphol; 2024 Aug; 32(7):309-321. PubMed ID: 38872345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin.
    Lin CH; Kuo KT; Chuang SS; Kuo SH; Chang JH; Chang KC; Hsu HC; Tien HF; Cheng AL
    Clin Cancer Res; 2006 Feb; 12(4):1152-6. PubMed ID: 16489068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germinal center B-cell-like versus non-germinal center B-cell-like as important prognostic factor for localized nodal DLBCL.
    Habara T; Sato Y; Takata K; Iwaki N; Okumura H; Sonobe H; Tanaka T; Orita Y; Abd Al-Kader L; Asano N; Ennishi D; Yoshino T
    J Clin Exp Hematop; 2012; 52(2):91-9. PubMed ID: 23037624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic Value of Morphology and Hans Classification in Diffuse Large B Cell Lymphoma].
    Wang KL; Chen C; Shi PF; Yu JH; Tan JF; Qian SX; Gao DQ; Chen K; Liu LR; Xie YP; Xu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1079-1085. PubMed ID: 30111411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Primary gastrointestinal diffuse large B-cell lymphoma: an immunohistochemical and prognostic study of 90 cases].
    Lin L; Min M; Bi CF; Wang XQ; Luo TY; Zhao S; Zhang WY; Liu WP
    Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):220-6. PubMed ID: 21615994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcome and prognostic factors in PCNSL.
    Niparuck P; Boonsakan P; Sutthippingkiat T; Pukiat S; Chantrathammachart P; Phusanti S; Boonyawat K; Puavilai T; Angchaisuksiri P; Ungkanont A; Chuncharunee S; Atichartakarn V
    Diagn Pathol; 2019 Jun; 14(1):56. PubMed ID: 31189479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated B-cell immunophenotype might be associated with poor prognosis of primary central nervous system lymphomas.
    Bhagavathi S; Sharathkumar A; Hunter S; Sung L; Kanhere R; Venturina MD; Wilson JD
    Clin Neuropathol; 2008; 27(1):13-20. PubMed ID: 18257470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy.
    Hong J; Park S; Park J; Jang SJ; Ahn HK; Sym SJ; Cho EK; Shin DB; Lee JH
    Ann Hematol; 2012 Dec; 91(12):1897-906. PubMed ID: 22864685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
    Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
    Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.